ArticleBreast (Edinburgh, Scotland)2026
Factors associated with local breast cancer recurrence after mastectomy in the Netherlands: a retrospective nationwide cohort study.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite presumed complete removal of glandular breast tissue, breast cancer (BC) patients can experience local recurrence (LR) after mastectomy. Most trials report recurrences as locoregional recurrence, potentially obscuring risk factors for LR. In this study, incidence of and risk factors for isolated LR after mastectomy were analysed.
methodsWomen diagnosed with primary unilateral nonmetastatic BC treated with mastectomy between 2012 and 2016 were selected from the Netherlands Cancer Registry. LR incidence was assessed within guideline-based indication groups. Multivariable Cox regression models were constructed for patients with and without primary systemic therapy (PST).
resultsIn total, 17,082 non-PST and 5033 PST patients were included, of whom 345 (2%) and 80 (1.6%) had LR after a median follow-up of 7.8 and 6.7 years, respectively. LR rates were low but varied between indication groups. In the non-PST group, screening detection, low grade, targeted therapy while HER2-positive, radiation therapy (RT), and adjuvant chemotherapy were associated with lower LR risk. Younger age, inner-quadrant location, higher tumour and nodal stage, immediate reconstruction, and omission of endocrine therapy were associated with higher LR risk. In the PST group, pathologic complete response, HER2-positivity, and RT were associated with lower LR risks, while higher clinical T stage, presence of ductal carcinoma in situ, and no endocrine therapy while hormone-receptor positive were associated with higher LR risk.
conclusionWe identified several factors associated with LR rates after mastectomy. Despite the observational character of our study, these factors could be considered in future treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.